Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K3ZL
|
|||
| Former ID |
DIB013942
|
|||
| Drug Name |
MA09-hRPE cells
|
|||
| Synonyms |
Retinal pigment epithelium program, ACT; MA09-hRPE cells (ocular disease); Embryonic stem-derived retinal pigmented epithelial cell therapy (ocular disease), CHA Bio Diostech; Stem cell-derived therapy (macular degeneration), Advanced Cell Technology; Retinal pigment epithelium program, (ocular disease), CHA Bio & Diostech; Stem cell-derived therapy (ocular disease), CHA Bio & Diostech; MA09-hRPE cells (ocular disease), Advanced Cell Technology/CHA Bio & Diostech; ES-derived RPE cell therapy (retinitis pigmentosa/Stargardt's disease/AMD), ACTC; Embryonic stem-derived retinal pigmented epithelial cell therapy (retinitis pigmentosa/Stargardt's disease/age related macular degeneration), Advanced Cell Technology; HESC-derived RPE cells (retinitis pigmentosa/Stargardt's disease/age related macular degeneration/ocular disease), Advanced Cell Technology
Click to Show/Hide
|
|||
| Indication | Stargardt disease [ICD-11: 9B70; ICD-10: H35.5] | Phase 1/2 | [1] | |
| Company |
Advanced Cell Technology Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.